ARQT Q3 2024 Earnings — Arcutis Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ARQTArcutis Biotherapeutics, Inc.

$3B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$45M+17.4% YoY

Gross Profit

$39M87.7% margin

Operating Income

-$39M-87.3% margin

Net Income

-$42M-92.8% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

+45.0%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$35M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$437M

Total Liabilities

$281M

Stockholders' Equity

$157M

Cash & Equivalents

$135M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$45M	$38M	+17.4%
Gross Profit	$39M	$37M	+6.3%
Operating Income	-$39M	-$37M	-5.9%
Net Income	-$42M	-$45M	+7.2%